PROTEOME SCIENCES plc
("Proteome Sciences" or the "Company")
PRESS RELEASE
Statement re Share Price Movement
The Board of Proteome Sciences has noted the recent movement in the Company's
share price and that they are not aware of any reason for the share price
increase.
In the trading update released on 21 December 2007, the Board reported that it
continued to view future prospects for TMT® commercialisation with increasing
confidence, with the related licence negotiations expected to be concluded in
early 2008. This remains the case and the Company will issue a further update
on licence negotiations in due course.
Ends
For further information please visit www.proteomics.com.
Proteome Sciences plc
Christopher Pearce James Malthouse
Chief Executive Officer Finance Director
christopher.pearce@proteomics.com james.malthouse@proteomics.com
Tel: +44 (0)1932 865065
Public Relations
IKON Associates Coast Communications
Adrian Shaw Matt Baldwin
Tel: +44 (0)1483 535102 Tel: +44 (0)1233 503200
Mobile: +44 (0)797 9900733 Mobile: +44 (0)7930 439739
adrian@ikonassociates.com matt@coastcommunications.com
Nominated Adviser
Landsbanki Securities (UK) Limited
Gareth Price / Thilo Hoffman Tel: +44 (0)20 7426 9000
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.